Ethypharm
Ethypharm is a leading mid-size international specialty pharmaceutical company, with strong European roots, that manufactures and provides essential medicines with a focus on Central Nervous System (severe pain and addiction) and Hospital Injectables. The company's mission is to improve patients’ lives by providing essential medicines and making a positive impact on society and the environment. Ethypharm is deeply engaged in CNS and Hospital Injectables, constantly screening opportunities to respond to unmet needs. It is a rapidly evolving company with significant growth ambitions, expanding through strategic geographical expansions and partnerships. Ethypharm has a strong industrial and commercial presence in Europe and China, with a global footprint in 68 countries, and operates six manufacturing sites. The company values diversity, sustainability, and ethical practices, and actively participates in community and environmental initiatives.
Industries
Nr. of Employees
Very Large (1000+)
Ethypharm
194 Bureaux de la Colline, Bâtiment D – 12ème étage, 92213 Saint-Cloud Cedex, France
Patents
Granules of an active substance with double taste-masking technique, method for the production thereof, and orodispersible tablets containing same
US-11872306-B2
View Details
Granules of an active substance with double taste-masking technique, method for the production thereof, and orodispersible tablets containing same
US-11872306-B2
View DetailsProducts
Immediate‑release orodispersible morphine formulations
Immediate‑release orodispersible tablet formulations of morphine developed in‑house and authorised for multiple European markets.
Injectable analgesic (Nefopam HCl) – injectable solution
Licensed injectable formulation of nefopam HCl for treatment of moderate to severe pain in hospital settings.
Argatroban monohydrate (antithrombin agent) – European portfolio
Acquired European rights to argatroban monohydrate for antithrombin therapy.
Mesalazine suppository formulation (China)
Suppository form of mesalazine added to the Chinese affiliate's local product portfolio.
Oral liquid angiotensin‑converting enzyme inhibitor formulations (captopril solution)
Oral liquid (solution) formulation of captopril for pediatric and other patients requiring liquid dosing.
Immediate‑ and extended‑release morphine capsule formulations
Extended‑release and immediate‑release morphine capsule formulations in multiple strengths for pain management.
Immediate‑release orodispersible morphine formulations
Immediate‑release orodispersible tablet formulations of morphine developed in‑house and authorised for multiple European markets.
Injectable analgesic (Nefopam HCl) – injectable solution
Licensed injectable formulation of nefopam HCl for treatment of moderate to severe pain in hospital settings.
Argatroban monohydrate (antithrombin agent) – European portfolio
Acquired European rights to argatroban monohydrate for antithrombin therapy.
Mesalazine suppository formulation (China)
Suppository form of mesalazine added to the Chinese affiliate's local product portfolio.
Oral liquid angiotensin‑converting enzyme inhibitor formulations (captopril solution)
Oral liquid (solution) formulation of captopril for pediatric and other patients requiring liquid dosing.
Immediate‑ and extended‑release morphine capsule formulations
Extended‑release and immediate‑release morphine capsule formulations in multiple strengths for pain management.
Services
Development and manufacturing services for third‑party pharmaceutical partners, including formulation, scale‑up and commercial supply.
Negotiation and execution of licensing agreements and exclusive commercialization partnerships for new products and territories.
Support for regulatory filings including European decentralized procedures and local registrations in China.
Direct commercial operations in major European markets and China plus distribution partnerships in other regions.
Development and manufacturing services for third‑party pharmaceutical partners, including formulation, scale‑up and commercial supply.
Negotiation and execution of licensing agreements and exclusive commercialization partnerships for new products and territories.
Support for regulatory filings including European decentralized procedures and local registrations in China.
Direct commercial operations in major European markets and China plus distribution partnerships in other regions.
Expertise Areas
- Central nervous system therapeutics (severe pain and addiction)
- Hospital and critical‑care injectables
- Complex generics and formulation development
- Sterile manufacturing and lyophilization
Key Technologies
- Good Manufacturing Practices (GMP)
- Modified‑release oral formulations
- Orodispersible tablet formulation
- Lyophilization (freeze‑drying)
News & Updates
Ethypharm Iberia signed a licensing agreement with Medochemie to commercialize Nefopam in Spain.
Ethypharm has taken back the distribution of Recivit® (fentanyl) in France.
Ethypharm and Laboratoires CTRS announced an exclusive agreement for the registration and commercialization of Orphacol in China.
Ethypharm completed the acquisition of Altan Pharma, expanding its presence in Spain and its R&D pipeline.
This certification reflects Ethypharm’s commitment to a CSR approach that is fully integrated into its development and respects all its stakeholders.
Ethypharm Iberia signed a licensing agreement with Medochemie to commercialize Nefopam in Spain.
Ethypharm has taken back the distribution of Recivit® (fentanyl) in France.
Ethypharm and Laboratoires CTRS announced an exclusive agreement for the registration and commercialization of Orphacol in China.
Ethypharm completed the acquisition of Altan Pharma, expanding its presence in Spain and its R&D pipeline.
This certification reflects Ethypharm’s commitment to a CSR approach that is fully integrated into its development and respects all its stakeholders.